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BRD4, a bromodomain and extraterminal domain
(BET) family member, is an attractive target in multi-
ple pathological settings, particularly cancer. While
BRD4 inhibitors have shown some promise in MYC-
driven malignancies such as Burkitt’s lymphoma
(BL), we show that BRD4 inhibitors lead to robust
BRD4 protein accumulation, which may account for
their limited suppression ofMYC expression, modest
antiproliferative activity, and lack of apoptotic induc-
tion. To address these limitations we designed ARV-
825, a hetero-bifunctional PROTAC (Proteolysis Tar-
getingChimera) that recruits BRD4 to the E3 ubiquitin
ligase cereblon, leading to fast, efficient, and pro-
longed degradation of BRD4 in all BL cell lines tested.
Consequently, ARV-825 more effectively suppresses
c-MYC levels and downstream signaling than small-
molecule BRD4 inhibitors, resulting in more effective
cell proliferation inhibition and apoptosis induction
in BL. Our findings provide strong evidence that cer-
eblon-based PROTACs provide a better and more
efficient strategy in targeting BRD4 than traditional
small-molecule inhibitors.
INTRODUCTION
BRD4 belongs to the bromodomain and extraterminal domain
(BET) family of proteins, which is characterized by two bromodo-
mains (BD) at the N terminus and an extraterminal domain (ET
domain) at the C terminus (Belkina and Denis, 2012; Shi and Va-
koc, 2014). The two BDs recognize and interact with acetylated
lysine residues at the N-terminal tails of histones; the ET domain,
which is not yet fully characterized, is largely considered to serve
a scaffolding function in recruiting diverse transcriptional regula-
tors (Belkina and Denis, 2012; Shi and Vakoc, 2014). Thus, BRD4
plays a key role in regulating gene expression by recruiting rele-
vant transcription modulators to specific genomic loci. Several
recent studies establish that BRD4 is preferentially located at su-
per-enhancer regions, which often reside upstream of important
oncogenes such as c-myc, bcl-xL, and bcl-6, and play a key roleChemistry & Biology 22,in regulating their expressions (Chapuy et al., 2013; Loven et al.,
2013). Owing to its pivotal role in modulating the expression of
essential oncogenes, BRD4 has emerged as a promising thera-
peutic target in multiple cancer types, including midline carci-
noma, acute myeloid leukemia (AML), multiple myeloma (MM),
Burkitt’s lymphoma (BL), and prostate cancer (Asangani et al.,
2014; Delmore et al., 2011; French et al., 2008; Loven et al.,
2013; Mertz et al., 2011; Wyce et al., 2013; Zuber et al., 2011).
In particular, BRD4 is exciting as an alternative strategy for
targeting c-MYC, which contributes to the development and
maintenance of a majority of human cancers but has remained
undruggable (Baratta et al., 2015; Delmore et al., 2011; Gabay
et al., 2014; Mertz et al., 2011). Indeed, the development
of small-molecule BRD4 inhibitors, such as JQ1, iBET, and
OTX015, has quickly demonstrated their promising therapeutic
potential in preclinical models of various cancers, including BL
(Asangani et al., 2014; Baratta et al., 2015; Boi et al., 2015; Cha-
puy et al., 2013; Delmore et al., 2011; Loven et al., 2013; Mertz
et al., 2011; Puissant et al., 2013). Almost all BL cancers contain
a c-myc gene translocation that places it under control of a
super-enhancer located upstream of IgH, thus driving an abnor-
mally high level of c-MYC expression, crucial to tumor develop-
ment and maintenance (Klapproth and Wirth, 2010). Excitingly,
preclinical studies with BRD4 inhibitors demonstrate their value
in suppressing c-MYC and proliferation in BL cell lines, albeit
with IC50 (half maximal inhibitory concentration) values often in
the range of 100 nM to 1 mM (Ceribelli et al., 2014; Mertz et al.,
2011).
Small-molecule inhibitors, either by inhibiting an enzyme activ-
ity (such as kinase inhibitors) or by interfering with protein-pro-
tein interactions (such as BRD4 inhibitors) have been the corner-
stone of drug development in oncology (Hoelder et al., 2012).
However, given the reversible binding of most small-molecule
inhibitors, large systemic drug concentrations and continuous
exposures are often required to ensure sufficient functional
inhibition (Johnson et al., 2010). In a number of cases it proves
challenging to achieve and maintain a drug concentration high
enough for efficacy in vivo. As an alternative, approaches to
eliminate disease-causing abnormal proteins, either by RNAi or
small-molecule-induced protein degradation, are evolving as
novel strategies for targeting the undruggable or difficult targets
(Burnett et al., 2011; Howell et al., 2004). We have developed an
induced protein degradation strategy that utilizes Proteolysis
Targeting Chimeras (PROTACs) that recruit targeted proteins755–763, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 755
to the E3 ubiquitin ligase VHL (Von Hippel-Lindau) for ubiquitina-
tion and subsequent proteasome-mediated degradation (Buck-
ley and Crews, 2014; Raina and Crews, 2010; Sakamoto et al.,
2001, 2003; Schneekloth and Crews, 2005; Schneekloth et al.,
2004). This PROTAC technology provides great potential in har-
nessing the action of a single E3 ligase toward pathologically
important proteins that are currently undruggable through con-
ventional strategies for drug development.
In this study, we demonstrate that the small-molecule BRD4
inhibitors, JQ1 and OTX015, lead to significant BRD4 protein
accumulation over time in all BL cell lines tested. Although
both inhibitors initially suppress downstream c-MYC level, the
suppression is incomplete and requires high drug concentra-
tions. This robust accumulation of BRD4, together with the
reversible nature of inhibitor binding to BRD4, may in part ac-
count for the modest effect of these inhibitors on downstream
c-MYC suppression and cell proliferation inhibition. To circum-
vent these limitations, we designed a hetero-bifunctional mole-
cule, ARV-825, by connecting a small-molecule BRD4 binding
moiety (OTX015) to an E3 ligase cereblon binding moiety (poma-
lidomide) using PROTAC technology (Boi et al., 2015; Fischer
et al., 2014; Ito et al., 2010). OTX015 is currently in phase I clinical
trials and pomalidomide is a potent third-generation immuno-
modulatory drug (IMiD), which functions through interacting
with the E3 ligase cereblon and inducing degradation of essential
Ikaros transcription factors in MM (Boi et al., 2015; Lu et al.,
2014). ARV-825 actively recruits BRD4 to cereblon, resulting in
the rapid and efficient degradation of the former via the protea-
some.We demonstrate that, compared with the BRD4 inhibitors,
ARV-825 treatment results in a strikingly more pronounced effect
on the levels of c-MYC, and downstream cell proliferation and
apoptosis induction in BL cell lines. These findings strongly sup-
port the development of BRD4 PROTACs as a promising novel
strategy to efficiently target BRD4. Moreover, this study is the
first to describe a potent PROTAC that acts via the recruitment
of the E3 ligase cereblon, Our study demonstrates that hijacking
the E3 ubiquitin ligase cereblon, or other E3 ligases, through the
PROTAC platform, holds great potential for pursuing effective
therapeutics.
RESULTS
Small-Molecule BET Domain Inhibitors Lead to
Significant BRD4 Protein Accumulation and Inefficient
c-MYC Suppression
As recently discovered, BL cells are responsive to BRD4 inhibi-
tors, mostly due to their dependence on the c-myc oncogene
that is translocated and brought under the control of upstream
IgH super-enhancers regulated by BRD4 (Klapproth and Wirth,
2010; Mertz et al., 2011). Interestingly, we found that both JQ1,
the most frequently used inhibitor in published studies, and
OTX015, the most advanced inhibitor in clinical development,
led to significant BRD4 protein accumulation in a dose-depen-
dent manner in all BL cell lines tested (Figure 1A and Figure S1).
This is consistent with the previously reported observation that
JQ1 treatment results in BRD4 upregulation in some lung cancer
cell lines (Shimamura et al., 2013). Moreover, the accumulation
of BRD4 is rapid, resulting in a multi-fold increase of BRD4within
24 hr of treatment (Figure 1B). We reasoned that the BRD4 inhib-756 Chemistry & Biology 22, 755–763, June 18, 2015 ª2015 Elsevieritor-induced increase in BRD4 protein level may incur a higher
barrier for BRD4 to be effectively suppressed. Indeed, even at
concentrations up to 10-fold over their IC50 values, JQ1 and
OTX015 were unable to suppress c-MYC levels fully (Figure 1C).
Even though a higher BRD4 level does not necessarily warrant
higher BRD4 nuclear localization under these conditions, this
finding implies that cancer cells may quickly restore their tran-
scriptional activation upon the withdrawal of bromodomain in-
hibitors. Indeed, c-MYC levels were rapidly restored to normal
upon the withdrawal of JQ1 and OTX015 from the culture media
(Figure 1D). This is consistent with previous findings in AML that
c-MYC is repressed by JQ1 treatment, but rebounds quickly
upon JQ1 withdrawal (Mertz et al., 2011).
Hijacking the E3 Ubiquitin Ligase Cereblon to Create
PROTAC to Efficiently Degrade BRD4
We noted the rapid and robust accumulation of BRD4 associ-
ated with inhibitor treatments, and the resulting moderate
effects on downstream c-MYC suppression and proliferation.
To circumvent these limitations, we used PROTAC technology
to design the chimeric small molecule ARV-825 (Figure 2A).
ARV-825 consists of a classic BRD4 binding moiety of the tria-
zolo-diazepine acetamide class seen in OTX015, and pomalido-
mide, a known cereblon bindingmoiety of the IMiD class (Fischer
et al., 2014), connected by a flexible polyethylene glycol linker.
This linker was chosen because of its high conformational
flexibility that would maximize the chance of the PROTAC
associating with both BRD4 and cereblon. We subsequently
demonstrated that ARV-825 shows only slightly reduced binding
affinities to bromodomains 1 and 2 compared with those of
OTX015 (Table 1).
Next, we showed that treatment of BL cell lines with ARV-825
results in almost complete BRD4 protein degradation, with DC50
(50% of maximum degradation) below 1 nM (Figure 2B). Given
that BRD4 and cereblon binding moieties in ARV-825 have Kds
of 28–90 nM and 3 mM to their respective targets (Table 1) (Lo-
pez-Girona et al., 2012), this suggests that ARV-825 acts in a
substoichiometric way in mediating BRD4 degradation. Interest-
ingly, we observed a bell-shaped dose dependence of BRD4
degradation by ARV-825 treatment, with some BRD4 protein re-
maining at the high concentration of 1 mM (Figure 2B). This phe-
nomenon argues for a BRD4/ARV-825/cereblon trimer complex
as the active species in driving efficient BRD4 degradation. High
concentrations of ARV-825 would be predicted to result in the
formation of non-functional BRD4/ARV-825 and ARV-825/
cereblon dimers that compete with formation of the active trimer,
resulting in lower BRD4 degradation (Figure S2). The BRD4
degradation induced by ARV-825 occurs rapidly, resulting in
more than 50% of protein being lost within 2 hr of compound
treatment (Figure 2B).
To confirm that BRD4 degradation induced by ARV-825 is
mediated by cereblon, we treated BL cells with ARV-825 in the
presence of an excess of the cereblon ligand pomalidomide.
As expected, the excess pomalidomide was able to reduce
ARV-825-induced BRD4 protein degradation, confirming a cere-
blon-mediated mechanism. Pomalidomide treatment by itself
in the same experiment had no impact on BRD4 protein levels
(Figure 2C). Furthermore, co-treatment with a proteasome
inhibitor (MG132 or carfilzomib) completely blocked the BRD4Ltd All rights reserved
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Figure 1. Small-Molecule BRD4 Inhibitors
Lead to Significant BRD4 Accumulation
and Inefficient c-MYC Suppression
(A) Small-molecule BRD4 inhibitors lead to signif-
icant BRD4 accumulation. Namalwa and Ramos
cells were treated overnight with increasing doses
of JQ1 and OTX015; lysates were collected and
subjected to immunoblot analysis with antibodies
for BRD4 and actin.
(B) Small-molecule BRD4 inhibitors lead to rapid
BRD4 accumulation. Namalwa and Ramos cells
were treated with 0.3 mM of JQ1 or OTX015 for
various times as indicated; lysates were collected
and analyzed by immunoblot for BRD4 and actin.
(C) Small-molecule BRD4 inhibitors lead to
downstream c-MYC suppression, but not effi-
ciently. Namalwa cells were treated overnight with
increasing doses of JQ1 andOTX015; lysateswere
collected and analyzed by immunoblot with anti-
bodies for c-MYC and actin.
(D) Loss of c-MYC suppression shortly after BRD4
inhibitors withdrawal. (Left) Namalwa cells were
treated with JQ1 (1.0 mM) for 24 hr, followed by
three washes to remove compounds. Cells were
re-seeded for lysate collection at various time
points, and c-MYC level was determined by
immunoblot. (Right) Ramos cells were treated with
JQ1 (1.0 mM) or OTX015 (1.0 mM) for 24 hr, followed
by removal of compounds and re-seeding in fresh
medium for 4 hr; lysates were subjected for
immunoblot with c-MYC and actin antibodies.degradation induced by ARV-825 (Figure 2D). Taken together,
these data demonstrate that ARV-825 leads to fast and efficient
BRD4 degradation in a cereblon-mediated and proteasome-
dependent mechanism.
ARV-825 Leads to More Significant and Longer Lasting
c-MYC Suppression than Small-Molecule Inhibitors
Next, we performed a head-to-head comparison between ARV-
825 and the small-molecule inhibitors JQ1 andOTX015, to deter-
mine their effects on BRD4 and c-MYC levels. JQ1 or OTX015
treatment consistently leads to robust BRD4 accumulation and
inefficient c-MYC suppression (Figure 3A). In contrast, ARV-
825 results in significant BRD4 degradation and a more pro-Chemistry & Biology 22, 755–763, June 18, 2015nounced downregulation of c-MYC
when compared with that seen with JQ1
and OTX015 treatment at higher concen-
trations (Figure 3A). Moreover, the sup-
pression of BRD4 and c-MYC protein
levels by ARV-825 is long lasting (Fig-
ure 3B). Namalwa cells were treated
with ARV-825, JQ1, or OTX015 for 24 hr,
then washed with fresh medium three
times to remove compounds. c-MYC re-
covers to the control level 4 hr after the
removal of JQ1 and OTX015 (Figure 3B).
In contrast, ARV-825 maintains both
BRD4 degradation and c-MYC suppres-
sion for up to 24 hr (Figure 3B). Consistent
with c-MYC suppression, its downstreamtarget gene, SLC19A1, is suppressed more substantially with
ARV-825 than with JQ1 and OTX015 treatments. Moreover,
SLC19A1 recovers to the control treatment level at 6 hr after
removal of JQ1 and OTX015, whereas ARV-825 sustains its ef-
fect on SLC19A1 repression significantly longer (Figure 3C).
ARV-825 Leads to a Superior Effect on Suppression of
BL Cell Proliferation Compared with BRD4 Inhibitors
BL cells are known to be sensitive to BRD4 inhibitors, which
suppress c-MYC signaling and inhibit cell proliferation (Mertz
et al., 2011). Because ARV-825 treatment results in prolonged
BRD4 downregulation and downstream signaling suppression
compared with BRD4 inhibitors, we hypothesized that it wouldª2015 Elsevier Ltd All rights reserved 757
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Figure 2. Hijacking the E3 Ubiquitin Ligase Cereblon to Create
PROTAC to Efficiently Degrade BRD4
(A) A schematic representation of bifunctional PROTAC ARV-825.
(B) ARV-825 leads to fast and efficient degradation of BRD4. (Top) Namalwa
and CA-46 cells were treated overnight with increasing doses of ARV-825;
lysates were analyzed for BRD4 levels by immunoblot with actin serving as
loading control. (Bottom) Namalwa and Ramos cells were treated with ARV-
825 (0.1 mM) for indicated time points; lysates were collected and subjected to
immunoblot analysis with antibodies for BRD4 and actin.
(C) Confirmation of cereblon-based mechanism in driving BRD4 degradation
upon ARV-825 treatment. Namalwa (left) and Ramos (right) cells were treated
overnight with various concentrations of ARV-825 or pomalidomide (10 mM),
or combination of ARV-825 and pomalidomide; lysates were analyzed by
immunoblot for BRD4 and actin.
(D) Confirmation of proteasome-based mechanism in driving BRD4 degra-
dation upon ARV-825 treatment. Namalwa cells were treated overnight with
ARV-825 (+, 0.01 mM; ++, 0.1 mM) alone, MG132 (5 mM), or carfilzomib (5 mM)
alone, or a combination of ARV-825 with MG132 or with carfizomib; lysates
were collected and analyzed by immunoblot for BRD4 and actin.
Table 1. Affinity to BD1 and BD2 of BRD4 by ARV-825, JQ1, and
OTX015
BD1 (nM) BD2 (nM)
ARV-825 90 28
JQ1 12 10
OTX015 14 3.5
Affinity of compounds with bromodomains 1 and 2 of BRD4 was deter-
mined with BROMOscan by DiscoverX.
758 Chemistry & Biology 22, 755–763, June 18, 2015 ª2015 Elsevierprovide superior functional effects compared with the inhibitors.
Indeed, ARV-825 leads to more pronounced suppression of pro-
liferation than both JQ1 and OTX015 in all BL cell lines tested
(Figure 4A). Moreover, the proliferation suppression effect of
ARV-825 is sustained longer than that of JQ1 and OTX015
after the removal of compounds following a 24-hr treatment (Fig-
ure 4B). This is consistent with our earlier findings that ARV-825
provides a long-lasting effect on BRD4 degradation and down-
stream signaling repression (Figures 3B and 3C). As demon-
strated in Figure 2C, the presence of excess cereblon ligand,
pomalidomide, is able to prevent efficient BRD4 degradation
induced by ARV-825 due to competition of cereblon binding.
The presence of excessive pomalidomide rescued the prolifera-
tion suppression effect of ARV-825 in BL cells in a dose-depen-
dent manner (Figure 4C). Importantly, pomalidomide alone did
not show any significant effects on the proliferation of these
cell lines (Figure 4D).
ARV-825 Leads to a Superior Effect on BLCell Apoptosis
Induction Compared with Small-Molecule Inhibitors
c-MYC is a pleiotropic oncoprotein involved in many hallmarks
of cancer, including cell cycle, senescence, proliferation, and
apoptosis, depending on the tumor (Gabay et al., 2014). We
have observed inhibition of proliferation in all BL lines tested
following treatment with both BRD4 inhibitors and ARV-825 (Fig-
ure 4). However, the effects on apoptosis are markedly different,
depending on the treatment. We observed increased caspase
3/7 activity after a 24-hr treatment of all four BL cell lines with
ARV-825, but not with a high dose of JQ1 and OTX015 (Fig-
ure 5A). By 48 hr, Ramos cells demonstrated significant
apoptosis with 0.1 mM ARV-825, as evidenced by prominent
poly(ADP-ribose) polymerase (PARP) cleavage (Figure 5B).
In contrast, significantly higher doses of inhibitors JQ1 and
OTX015 are needed to elicit a similar level of apoptosis in corre-
sponding cell lines, likely due to their inefficient BRD4 inhibition
and downstream c-MYC repression. Taken together, these find-
ings strongly corroborate that PROTAC-mediated BRD4 degra-
dation is an effective strategy in targeting BRD4 in BL.
DISCUSSION
BRD4 has captured considerable attention from academia and
the pharmaceutical industry alike due to its great potential as a
novel target in multiple disease settings, particularly in cancer.
One key advantage of BRD4 as an oncology target is that it is
identified as preferentially clustering at super-enhancer regions
in control of pivotal oncogenes such as c-myc, bcl-xl, and
pax5 (Chapuy et al., 2013; Loven et al., 2013), and thus offersLtd All rights reserved
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Figure 3. ARV-825 Leads to More Signifi-
cant and Longer Lasting c-MYC Suppres-
sion than Small-Molecule Inhibitors
(A) Namalwa (left) and Ramos (right) cells were
treated overnight with increasing doses of ARV-
825 (up to 1.0 mM), JQ1 (up to 10.0 mM), or OTX015
(up to 10.0 mM); lysates were analyzed by immu-
noblot for BRD4, c-MYC, and actin.
(B) Namalwa cells were treated for 24 hr with ARV-
825 (0.1 mM), JQ1 (1.0 mM), and OTX015 (1.0 mM),
followed by three washes to remove compounds,
and re-seeded in fresh medium for various time
points. Lysates were collected and analyzed by
immunoblot for BRD4, c-MYC, and actin.
(C) Namalwa cells were treated as in (B), RNA was
extracted at 0, 6, and 24 hr after compound
removal, reverse-transcribed into cDNA, and
quantified by qPCR with SLC19A1-specific
primers; GAPDH served as internal control. Error
bars represent the SEM.an alternative strategy in targeting those oncoproteins which are
difficult to inhibit by traditional strategies. Moreover, BRD4’s
distinct high occupancy of genomic loci proximal to specific on-
cogenes provides the potential for a therapeutic window that
could allow specific targeting of tumor cells while sparing normal
tissues. Indeed, BRD4 inhibitors have shown antitumor activities
with good tolerability in different mouse tumor models (Asangani
et al., 2014; Baratta et al., 2015; Boi et al., 2015; Ceribelli et al.,
2014; Chapuy et al., 2013; Loven et al., 2013; Mertz et al.,
2011; Shimamura et al., 2013; Wyce et al., 2013). Also, not sur-
prisingly, high sensitivity to BRD4 inhibitors, such as JQ1, has
been associated with high level of either c-MYC or n-MYC in
different tumor types, including c-MYC-driven BL (Baratta
et al., 2015; Loosveld et al., 2014; Mertz et al., 2011; Puissant
et al., 2013). Currently four BET bromodomain inhibitors are in
phase I clinical trials with a focus largely on midline carcinoma
and hematological malignancies (CPI-0610, NCT01949883;
GSK525762, NCT01587703; OTX015, NCT01713582; TEN-
010, NCT01987362). In this report, we found that the BRD4 inhib-
itors JQ1 and OTX015 lead to fast and robust accumulation ofChemistry & Biology 22, 755–763, June 18, 2015BRD4 protein in all BL cell lines tested.
Similar observations have been found in
a panel of lung and prostate cancer cell
lines (Shimamura et al., 2013). One
possible explanation is that the binding
of inhibitors to BRD4 results in a
conformational change, which leads to
increased thermodynamic stability of the
protein. Similarly, inhibitor binding could
hinder BRD4 accessibility to the endoge-
nous cellular degradation machinery,
thus rendering it kinetically stable. Alter-
natively, the BRD4 inhibitorsmay be inter-
rupting a BRD4-mediated negative feed-
back loop that regulates BRD4 protein
levels. Nevertheless, this prominent in-
crease of BRD4 levels, together with the
reversible nature of inhibitor binding,could prevent efficient BRD4 inhibition. Indeed, both preclinical
and clinical studies have shown that the effects of BRD4 inhibi-
tors are largely cytostatic, with apoptosis limited to a few cell
lines and tumors from phase I patients (Chapuy et al., 2013; Del-
more et al., 2011; Shao et al., 2014). This could significantly limit
the potential benefit of patients at clinically achievable concen-
trations of BRD4 inhibitors. One strategy to achieve more effec-
tive BRD4 inhibition is to design irreversible/covalent inhibitors,
which have revived significant interest in recent years, as they
may achieve the desired pharmacological effect at lower drug
concentrations (Johnson et al., 2010). However, covalent
inhibitors have their own limitations, most notably the potential
immunogenicity of protein adduct and high hurdle of selectivity
(Johnson et al., 2010).
Here, we designed a novel chimera molecule, ARV-825, using
the PROTAC platform, to efficiently degrade BRD4, as an alter-
native strategy of targeting BRD4. In the process, we also
demonstrated for the first time the incorporation of the E3 ligase
cereblon into the PROTAC technology paradigm (Fischer et al.,
2014). We successfully achieved rapid and prominent BRD4ª2015 Elsevier Ltd All rights reserved 759
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Figure 4. ARV-825 Leads to a Superior Ef-
fect on Suppression of BL Cell Proliferation
Compared with BRD4 Inhibitors
(A) Various BL cell lines were seeded at 50,000
cells/100 ml in 96-well plates and then treated with
increasing doses of ARV-825, JQ1, and OTX015;
relative proliferation was determined by CellTiter-
Glow (CTG) assay 72 hr later.
(B) ARV-825 leads to longer lasting proliferation
suppression than small-molecule inhibitors. Na-
malwa cells were treated for 24 hr with ARV-825
(0.1 mM), JQ1 (1.0 mM), and OTX015 (1.0 mM), fol-
lowed by three washes to remove compounds,
and re-seeded in fresh medium in 96-well plates;
relative proliferation was determined by CTG
assay at 24 and 48 hr after re-seeding.
(C) Pomalidomide partially rescued the effect on
proliferation suppression by ARV-825 treatment.
Different BL cell lines were treated with ARV-825
(0.01 mM on left, 0.1 mMon right) alone, or together
with pomalidomide (1.0 or 10.0 mM) for 72 hr;
relative cell proliferation was determined by CTG
assay.
(D) Pomalidomide does not have a significant ef-
fect on BL cell proliferation. Different BL cell lines
were treated with increasing doses of pomalido-
mide (up to 10.0 mM) for 72 hr; relative proliferation
was determined by CTG assay.
Error bars represent the SEM.degradation by ARV-825, which leads to robust and long-lasting
downstream c-MYC suppression. Most importantly, ARV-825
results in more significant proliferation suppression, and more
robust apoptosis induction, than even high concentrations of
both JQ1 and OTX015. The improved functional effects of
BRD4 degrader over inhibitors could be partially attributed to
the more complete and sustained suppression on c-MYC, a
driver oncoprotein in BL. It is also possible that BRD4 possesses
scaffolding functions, as it is a large protein with many binding
partners, many of which remain to be identified and elucidated.
Understandably, eliminating BRD4 would elicit a more profound
effect than mere inhibition of its binding to acetyl lysine-contain-
ing partners. A comparison of phenotypes of BRD4 knockout or
knockdown (such as by CRISPR or shRNAs) with that of BRD4
inhibition by inhibitors would help inform this possibility. Such
an analysis, however, is beyond the scope of this report.760 Chemistry & Biology 22, 755–763, June 18, 2015 ª2015 Elsevier Ltd All rights reservedThe more complete and longer lasting
disruption of BRD4 function by PROTACs
or other means, on the one hand, will
benefit future patients because of the
more effective targeting and less frequent
dosing regimen. On the other hand,
it could also be associated with more
severe side effects, as BRD4 regu-
lates diverse biological processes in a
cellular context-dependent manner (Bol-
den et al., 2014; Fernandez et al., 2014).
Recent findings using an inducible and
reversible transgenic BRD4 targeting
RNAi mouse model have elegantly shed
some light on the potential limitations ofpotent and sustained BRD4 targeting, including epidermal hy-
perplasia, alopecia, and reduced cellular diversity and stem
cell loss in the small intestine (Bolden et al., 2014). This repre-
sents a dilemma commonly seen in drug development, namely,
determining whether and how an optimal therapeutic index can
be achieved in the clinic. Importantly, these on-target side ef-
fects of BRD4 suppression appear to be reversible, giving
hope that there will be a therapeutic window through better un-
derstanding and management of BRD4 targeted therapeutics
(Bolden et al., 2014).
Due to the high homology of BET family BD1 and BD2 do-
mains, current BET inhibitors in clinical development, including
OTX015, are not selective in binding and inhibiting BRD2/3/4/T
(Filippakopoulos et al., 2010; Noel et al., 2014). We also exam-
ined the effect of ARV-825 on BRD2 and BRD3 (BRDT is only ex-
pressed in testis). Not surprisingly, both BRD2 and BRD3, like
AB
Figure 5. ARV-825 Leads to a Superior Effect on BL Cell Apoptosis
Induction Compared with Small-Molecule Inhibitors
(A) Various BL cell lines were treated with ARV-825 (0.1 mM), JQ1 (1.0 mM),
OTX015 (1.0 mM), or puromycin (10 mg/ml) as positive control of apoptosis
induction, for 24 hr; caspase 3/7 activity was measured by Caspase-Glo 3/7
assay. Error bars represent the SEM.
(B) Ramos and CA-46 cells were treated with increasing doses of ARV-825 (up
to 1.0 mM), or JQ1 and OTX015 (up to 10.0 mM) for 48 hr. Lysates were
collected and analyzed by immunoblot for PARP cleavage with actin as
loading control.BRD4, can be degraded by ARV-825 (Figure S3) owing to the
similar affinity of OTX015 to all BET family members, and a large
number of overlapping surface lysines on all BET members.
However, PROTACs can provide more opportunities to achieve
better selectivity through the careful design of the ‘‘linker’’ region
that could increase/decrease affinities to various binding targets,
or could position its E3 ligase moiety for optimal surface lysine
presentation of specific targets. These hypotheses need exten-
sive investigation through both modeling and experimental
testing. If true, PROTACs, as a new class of drugmolecule, could
greatly benefit future patients across multiple disease areas.
Here, we report the first success PROTAC, which acts through
hijacking the E3 ligase cereblon by utilizing a clinically approved
IMiD pomalidomide. To further confirm that the degradation
mechanism of ARV-825 is through cereblon, we prepared a
direct analog of ARV-825 by methylating the NH group in the pi-
peridinedione fragment. Since this NH group is crucial in the
binding to cereblon His380 (PDB: 4CI3), N-Methylation is pre-Chemistry & Biology 22,dicted to cause significant loss of cereblon binding affinity. As
expected, N-methylated ARV-825 does not degrade BRD4 (Fig-
ure S4). Cereblon is a ubiquitously expressed protein, so this
approach can potentially apply to multiple disease settings in
various organs or tissues when different target protein recruiting
ligands are attached. Downregulation of cereblon has been pro-
posed as a mechanism of resistance to IMiDs in MM (Lopez-
Girona et al., 2012). In situations like this, alternative E3 ligases
with a known binding molecule could be utilized in designing
PROTAC therapies.
Binding affinity of OTX015 and pomalidomide to their respec-
tive targets, BRD4 and cereblon, are 10 nM and 3 mM,
respectively. Excitingly ARV-825, which is based on these two li-
gands, achieves a DC50 for BRD4 below 1 nM. This strongly sug-
gests that a BRD4 PROTAC is able to engage in multiple cycles
of protein degradation, and opens up opportunities to develop
functional degraders consisting of target ligands with insufficient
affinity to provide a functional effect. Therefore many targets,
which lack enzymatic active sites, but can be bound by small
molecules in shallow pockets, may become druggable with
PROTAC-mediated degradation.
In summary, we report a novel strategy to efficiently target
BRD4 by creating a potent BRD4 degrader through PROTAC
technology using the E3 ligase cereblon. This breaks ground
for a new class of drug molecules which actively recruits an E3
ligase to target specific pathological proteins for degradation,
thus rendering many drug targets refractory to traditional
small-molecule approaches now druggable.
SIGNIFICANCE
In this study, we designed a novel bifunctional PROTAC
molecule, which contains a BRD4 recruiting moiety and an
E3 ligase cereblon recruiting moiety. Our BRD4 PROTAC
actively degrades BRD4, leading to significant and persis-
tent downstream c-MYC suppression and, most impor-
tantly, resulting in robust proliferation inhibition and
apoptosis induction in BL. BRD4 PROTAC represents a
new strategy to efficiently block BRD4, which is a promising
target in multiple cancers. Moreover, this study serves as an
example that PROTAC-mediated protein degradation pro-
vides a promising strategy to target undruggable patholog-
ical proteins.
EXPERIMENTAL PROCEDURES
Reagents
Namalwa, Ramos, CA-46, and DAUDI cells were purchased from ATCC and
maintained as instructed. Antibodies against BRD4 (#E2A7X), BRD2 (#5848),
c-MYC (#D84C12), and PARP (#46D11) were purchased from Cell Signaling
Technology. Actin (#A5441) antibody was purchased from Sigma-Aldrich.
BRD3 antibody (#2088c3a) was purchased from Santa Cruz Biotechnology.
Secondary antibodies (#7074, #7076) were purchased from Cell Signaling
Technology. MG132 (#M7449) was purchased from Sigma-Aldrich. Carfilzo-
mib (#S2853) was purchased from Selleck. JQ1 (Filippakopoulos et al.,
2010), OTX015 (Sueoka et al., 1998), and pomalidomide (Ge et al., 2007)
were synthesized according to methods published.
Western Blot Analysis
Cultured cells were collected in lysis buffer containing 40 mMHEPES (pH 7.4),
140 mM NaCl, 2.5 mM EDTA, 1% NP-40, 0.1% SDS, and protease inhibitor755–763, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 761
cocktail. After 10min of centrifugation (14,000 rpm), supernatant was collected
for protein concentration determination by the bicinchoninic acid method and
subjected for immunoblotting by standard protocol. Western blot results were
visualized using Bio-Rad Clarity ECLWestern Blotting Substrate on a Bio-Rad
ChemiDoc MP imaging system.
qRT-PCR
RNA extraction was performed with an Aurum Total RNA Mini Kit (#732-6820)
from Bio-Rad. First-strand cDNA from total RNA was synthesized with a High-
Capacity cDNA Reverse Transcription Kit (#4368813) from Life Technologies
according to the manufacturer’s instructions. qPCR was performed using
Bio-Rad SsoAdvanced Universal SYBR Green Supermix (#172-5271). Primers
used were GAPDH-F, GAAGGTGAAGGTCGGAGTC; GAPDH-R, GAAGATGG
TGATGGGATTTC; SLC19A1-F, ATGGCCCCCAAGAAGTAGAT; SLC19A1-R,
GTCAACACGTTCTTTGCCAC.
Proliferation and Caspase 3/7 Assays
To assess the effect of compounds on proliferation, cells (50,000/100 ml) were
seeded in 96-well tissue culture plates followed by addition of compound at
indicated concentrations. After 72 hr, 100 ml per well of reconstituted Cell-
Titer-Glo reagent (#G7572 from Promega) was added and read on a Cytation
3 imaging reader from BioTek. Relative cell growth was determined by
comparing assay readings of treated cells with control DMSO-treated cells.
For apoptosis induction, a Caspase-Glo 3/7 assay (#G8091 from Promega)
was used following the manufacturer’s instructions.
Compound Synthesis
The synthetic scheme and detailed experimental procedure for the preparation
of ARV-825 is described in Supplemental Experimental Procedures. The struc-
ture of ARV-825 was confirmed by 1H-nuclear magnetic resonance and liquid
chromatography/mass spectrometry. Purity of ARV-825 was more than 97%
based on high-performance liquid chromatography analysis.
Kd Determination
Affinity of compounds with bromodomains 1 and 2 of BRD4 was determined
with BROMOscan by DiscoverX.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.chembiol.2015.05.009.
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524–528.Note Added in Proof
While this paper was in production, a report came out online describing the
development of dBET1, a compound that utilizes the same PROTAC technol-
ogy used to develop ARV-825, and induces selective cereblon-dependent
BET protein degradation via the same mechanism as ARV-825 (http://dx.doi.
org/10.1126/science.aab143). Although ARV-825 and dBET1 were not
compared in the same assay, our data suggest that the increased potency
of BRD4 PROTAC in comparison with JQ1 is more significant in ARV-825 (Fig-
ure 4) than in dBET1. Based on a study of several BRD4 PROTAC molecules,
we observed that the linker connecting BRD4 and cereblon ligands can have
significant effects on the potency of BRD degradation, downstream c-Myc
suppression, and cell proliferation inhibition, which could explain the differ-
ence between ARV-825 and dBET1. More importantly, the identification of
dBET1 further provides strong validation for the development of novel thera-
peutics using the PROTAC technology.755–763, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 763
